HomeCompareASFX vs ARCC

ASFX vs ARCC: Dividend Comparison 2026

ASFX yields 5000000.00% · ARCC yields 10.82%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ASFX wins by $4.651129742658086e+43M in total portfolio value
10 years
ASFX
ASFX
● Live price
5000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.651129742658086e+43M
Annual income
$46,509,467,603,334,410,000,000,000,000,000,000,000,000,000,000,000.00
Full ASFX calculator →
ARCC
Ares Capital Corporation
● Live price
10.82%
Share price
$17.74
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.16
Full ARCC calculator →

Portfolio growth — ASFX vs ARCC

📍 ASFX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodASFXARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ASFX + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ASFX pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ASFX
Annual income on $10K today (after 15% tax)
$425,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$39,533,047,462,834,250,000,000,000,000,000,000,000,000,000,000,000.00/yr
ARCC
Annual income on $10K today (after 15% tax)
$919.95/yr
After 10yr DRIP, annual income (after tax)
$0.99/yr
At 15% tax rate, ASFX beats the other by $39,533,047,462,834,250,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ASFX + ARCC for your $10,000?

ASFX: 50%ARCC: 50%
100% ARCC50/50100% ASFX
Portfolio after 10yr
$2.325564871329043e+43M
Annual income
$23,254,733,801,667,206,000,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
100.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

ASFX
No analyst data
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+23.3% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ASFX buys
0
ARCC buys
0
No recent congressional trades found for ASFX or ARCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricASFXARCC
Forward yield5000000.00%10.82%
Annual dividend / share$2.00$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$4.651129742658086e+43M$24.5K
Annual income after 10y$46,509,467,603,334,410,000,000,000,000,000,000,000,000,000,000,000.00$1.16
Total dividends collected$4.651117771440442e+43M$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: ASFX vs ARCC ($10,000, DRIP)

YearASFX PortfolioASFX Income/yrARCC PortfolioARCC Income/yrGap
1← crossover$500,010,700$500,000,000.00$11,381$541.15+$500.00MASFX
2$23,365,520,992,757$23,364,985,981,308.41$12,621$284.08+$23365520.98MASFX
3$1,020,442,548,175,215,100$1,020,417,547,067,752,800.00$13,827$145.31+$1020442548175.20MASFX
4$41,650,346,151,752,480,000,000$41,649,254,278,225,940,000,000.00$15,062$73.43+$41650346151752480.00MASFX
5$1,588,787,048,835,084,000,000,000,000$1,588,742,482,964,701,800,000,000,000.00$16,364$36.89+$1.588787048835084e+21MASFX
6$56,640,860,400,245,200,000,000,000,000,000$56,639,160,398,102,940,000,000,000,000,000.00$17,757$18.49+$5.66408604002452e+25MASFX
7$1,887,170,449,619,629,000,000,000,000,000,000,000$1,887,109,843,899,000,500,000,000,000,000,000,000.00$19,258$9.25+$1.887170449619629e+30MASFX
8$58,763,764,792,023,670,000,000,000,000,000,000,000,000$58,761,745,519,642,570,000,000,000,000,000,000,000,000.00$20,880$4.63+$5.876376479202367e+34MASFX
9$1,710,115,183,602,138,000,000,000,000,000,000,000,000,000,000$1,710,052,306,373,811,000,000,000,000,000,000,000,000,000,000.00$22,636$2.32+$1.710115183602138e+39MASFX
10$46,511,297,426,580,864,000,000,000,000,000,000,000,000,000,000,000$46,509,467,603,334,410,000,000,000,000,000,000,000,000,000,000,000.00$24,539$1.16+$4.651129742658086e+43MASFX

ASFX vs ARCC: Complete Analysis 2026

ASFXStock

American Scientific Resources, Incorporated develops, manufactures, assembles, markets, and distributes medical products and devices for children and adults. It offers Thermofocus 5-in-1, a non-contact clinical thermometer; VeraTemp and VeraTemp+ non-contact thermometers; Scald Safe Water temperature disc, a warning disc that helps to ensure that a baby's bath water is at an appropriate temperature; and WhistleWatch, a flow monitoring device that allows parents to monitor their child's respiratory problems. The company also provides Kidz-Med portable ultrasonic nebulizer, which is used to treat asthma, bronchitis, allergies, and sinusitis; Kidz-Med Medicine Dispenser that consists of an orthodontic nipple attached to a medication chamber; and Kidz-Med Mommy Recorder, a voice-recording device, which allows a mother to record a message designed to calm baby when he or she is upset. In addition, it offers Bip DVDs, a video series to help children understand life events; Mebby product line that includes breast pumps, bisphenol A free baby bottles, digital scales, humidifiers, pacifiers, & sterilizers; and Wee Target, a toilet training device for young boys. Further, the company provides Disintegrator, a home needle and lancet destruction device, which enables patients who give themselves injections, including those suffering from multiple sclerosis or diabetes to properly and safely dispose of needles at home. American Scientific Resources distributes its products primarily through retail drug and grocery chains, and medical suppliers, as well as through its Web site and other on-line sites. The company is based in Weston, Florida. On February 27, 2012, an involuntary petition for liquidation under Chapter 7 was filed against American Scientific Resources, Incorporated in the US Bankruptcy Court for the Southern District of Florida. On March 28, 2012, the involuntary petition was approved by the Court. American Scientific Resources, Inc. is in liquidation.

Full ASFX Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this ASFX vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ASFX vs SCHDASFX vs JEPIASFX vs OASFX vs KOASFX vs MAINASFX vs HTGCASFX vs GBDCASFX vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.